Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

NCT05070364 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis Delta Virus

Interventions

DRUG: Peginterferon Lambda-1a

Sponsor

Eiger BioPharmaceuticals